In the past week, RNAC stock has gone down by -6.02%, with a monthly decline of -28.43% and a quarterly plunge of -9.78%. The volatility ratio for the week is 11.84%, and the volatility levels for the last 30 days are 14.19% for Cartesian Therapeutics Inc The simple moving average for the last 20 days is -18.55% for RNAC’s stock, with a simple moving average of -32.21% for the last 200 days.
Is It Worth Investing in Cartesian Therapeutics Inc (NASDAQ: RNAC) Right Now?
The stock has a 36-month beta value of 0.63. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAC is 6.94M, and at present, short sellers hold a 16.63% of that float. On July 19, 2024, the average trading volume of RNAC was 149.71K shares.
RNAC) stock’s latest price update
Cartesian Therapeutics Inc (NASDAQ: RNAC)’s stock price has dropped by -9.39 in relation to previous closing price of 18.42. Nevertheless, the company has seen a loss of -6.02% in its stock price over the last five trading days. globenewswire.com reported 2024-07-08 that GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of 35,198 shares of the Company’s common stock with an exercise price of $24.27, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. Each of the options vest as to 25% on July 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on July 1, 2028. Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
Analysts’ Opinion of RNAC
Oppenheimer, on the other hand, stated in their research note that they expect to see RNAC reach a price target of $50. The rating they have provided for RNAC stocks is “Outperform” according to the report published on June 04th, 2024.
Mizuho gave a rating of “Buy” to RNAC, setting the target price at $40 in the report published on May 24th of the current year.
RNAC Trading at -33.36% from the 50-Day Moving Average
After a stumble in the market that brought RNAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.82% of loss for the given period.
Volatility was left at 14.19%, however, over the last 30 days, the volatility rate increased by 11.84%, as shares sank -23.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.16% lower at present.
During the last 5 trading sessions, RNAC fell by -6.02%, which changed the moving average for the period of 200-days by -47.52% in comparison to the 20-day moving average, which settled at $20.24. In addition, Cartesian Therapeutics Inc saw -19.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAC starting from SPRINGER TIMOTHY A, who purchase 19,044 shares at the price of $0.60 back on Mar 18 ’24. After this action, SPRINGER TIMOTHY A now owns 31,073,406 shares of Cartesian Therapeutics Inc, valued at $11,398 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Cartesian Therapeutics Inc, purchase 800 shares at $0.61 during a trade that took place back on Mar 18 ’24, which means that SPRINGER TIMOTHY A is holding 104,818 shares at $488 based on the most recent closing price.
Stock Fundamentals for RNAC
Current profitability levels for the company are sitting at:
- -3.13 for the present operating margin
- 0.95 for the gross margin
The net margin for Cartesian Therapeutics Inc stands at -9.84. The total capital return value is set at -0.28. Equity return is now at value -49.79, with -121.61 for asset returns.
Based on Cartesian Therapeutics Inc (RNAC), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -5.58. The debt to equity ratio resting at -0.09. The interest coverage ratio of the stock is -40.04.
Currently, EBITDA for the company is -84.88 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 7.89. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.03.
Conclusion
To sum up, Cartesian Therapeutics Inc (RNAC) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
